ENDPOINTS

Plus, news about MeiraGTx, Hookipa and Pool­beg Phar­ma: A pair of $500M share buy­backs: Ex­elix­is and Sign up to read this article for free. Get

Plus, news about Basilea, TME Phar­ma and Per­ceive Bio­ther­a­peu­tics: Septer­na stops work on Phase 1: The new­ly pub­lic biotech Sign up to read this article

Plus, news about Aard­vark’s IPO: Ot­su­ka cuts can­cer pro­grams: The drug­mak­er is stop­ping de­vel­op­ment of OPB-111077, an oral STAT in­hibitor, for … Sign up to

Plus, news about Pli­ant Ther­a­peu­tics, Blue­print Med­i­cines, Gala­pa­gos and Atai: Pain biotech rais­es $45M: Al­lay Ther­a­peu­tics, which is de­vel­op­ing non-opi­oid anal­gesics pain … Sign up

Plus, news about Odyssey Ther­a­peu­tics, GSK, Ali­gos Ther­a­peu­tics, Ter­rain Bio­sciences, the Gates Foun­da­tion and Ne­upho­ria Ther­a­peu­tics: Bio­gen ap­pears to back away from deal­mak­ing pro­jec­tions: The

Plus, news about Arv­inas and In­vizyne Tech­nolo­gies: IN8bio’s Phase 1 da­ta in acute myeloid leukemia: In an in­ves­ti­ga­tor-spon­sored study, all nine pa­tients who re­ceived the

Plus, news about Cali­way Bio­phar­ma­ceu­ti­cals, Or­ca Bio, Al­ter­i­ty Ther­a­peu­tics and As­cen­t­age Phar­ma: Roivant dis­con­tin­ues rare lung dis­ease drug: The ter­mi­na­tion, dis­closed in Roivant’s Sign up

Plus, news about X4 Phar­ma­ceu­ti­cals, Virac­ta Ther­a­peu­tics, Crown Lab­o­ra­to­ries, Qlaris and Hi­tachi. Affy­Im­mune’s lay­offs: The CAR-T biotech went through a round of lay­offs and re­struc­tur­ing

Plus, news about Au­ron Ther­a­peu­tics, Akribion Ther­a­peu­tics, En­ver­ic Bio­sciences and Va­le­rio Ther­a­peu­tics: Turn­stone Bi­o­log­ics to dis­con­tin­ue TIL stud­ies, “re­view strate­gic al­ter­na­tives”: The com­pa­ny Sign up